Key Market Indicators
Mexican pharmaceutical research and development (R&D) expenditures are projected to plummet to approximately $44 million purchasing power parity (PPP) by 2028. This marks a significant decline from the $75 million PPP recorded in 2023, averaging an 8.3% decrease annually. The decline in Mexico's pharmaceutical supply has been a long-term trend, with a yearly average drop of 6.1% since 1999. As of 2023, Mexico ranked 14th globally in pharmaceutical R&D spending. The Czech Republic surpassed Mexico in 2023, also reporting expenditures of $75 million PPP. Leading the global rankings were China, Germany, and South Korea, holding the second, third, and fourth positions, respectively.
